Cmt Prep Challenge #48

Front 1

Prescribed to treat symptoms of Alzheimer disease, this medication is thought to improve memory by increasing acetylcholine levels in the brain, thereby improving cholinergic neurotransmission. It is available as 5 mg and 10 mg film-coated tablets. The usual dosage is 5 to 10 mg once daily in patients with mild to moderate symptoms and 10 mg once daily in patients with severe Alzheimer disease. This medication is generally well tolerated; however, side effects such as nausea, diarrhea, insomnia, and anorexia may occur.



A Lunesta (eszopiclone)
B Strattera (atomoxetine)
C Emend (aprepitant)
D Geodon (ziprasidone)
E Comtan (entacapone)
F Cymbalta (duloxetine)
G Amerge (naratriptan)
H Lyrica (pregabalin)
I Aricept (donepezil)
J Rilutek (riluzole)

Back 1

I Aricept (donepezil)

Front 2

Although this medication is most recognized for its use in the treatment of major depressive disorder and generalized anxiety disorder, it is also used to treat neuropathic pain associated with diabetic neuropathy. It is available as 20 mg, 30 mg, and 60 mg capsules. The usual initial dosage to treat major depressive disorder is 20-30 mg twice daily for 1 week, titrated to a maintenance dosage of 60-120 mg once daily. The dosage to treat generalized anxiety disorder begins with 30 mg once daily, titrated to a maintenance dosage of 60-120 mg once daily. To treat pain associated with diabetic neuropathy, patients are usually started with a dosage of 60 mg daily, which may be titrated up to 120 mg daily. This medication should not be administered to patients with kidney or liver impairment. Common side effects may include nausea, dry mouth, dizziness, insomnia, fatigue, somnolence, constipation, decreased appetite, and hyperhidrosis (profuse sweating).



A Lunesta (eszopiclone)
B Strattera (atomoxetine)
C Emend (aprepitant)
D Geodon (ziprasidone)
E Comtan (entacapone)
F Cymbalta (duloxetine)
G Amerge (naratriptan)
H Lyrica (pregabalin)
I Aricept (donepezil)
J Rilutek (riluzole)

Back 2

F Cymbalta (duloxetine)

Front 3

This medication is indicated as an adjunct to levodopa/carbidopa treatment in patients with Parkinson disease who are experiencing a "wearing-off" effect. It helps improve the effectiveness of levodopa/carbidopa by inhibiting the breakdown of levodopa in the blood, thereby increasing levodopa blood levels. It is available as 200 mg film-coated tablets. The usual dosage is one tablet administered with levodopa/carbidopa, up to 8 times daily. Common adverse effects are dyskinesia, hyperkinesia, nausea, urine discoloration, diarrhea, and abdominal pain.



A Lunesta (eszopiclone)
B Strattera (atomoxetine)
C Emend (aprepitant)
D Geodon (ziprasidone)
E Comtan (entacapone)
F Cymbalta (duloxetine)
G Amerge (naratriptan)
H Lyrica (pregabalin)
I Aricept (donepezil)
J Rilutek (riluzole)

Back 3

E Comtan (entacapone)

Front 4

Classified as a selective norepinephrine reuptake inhibitor, this medication is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It is available as 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg capsules. This medication may be administered either once daily in the morning or twice daily, in the morning and late afternoon. The initial dosage in children and adolescents up to 70 kg is 0.5 mg/kg/day, increased to a target maintenance dosage of 1.2 mg/kg/day. The maximum dosage for patients 6 to 15 years of age is 1.8 mg/kg/day. The initial dosage in patients over 70 kg is 40 mg/day, increased to a target maintenance dosage of 80 mg/day, with a maximum of 100 mg/day. Common adverse effects are nausea, vomiting, abdominal pain, decreased appetite, headache, and somnolence.



A Lunesta (eszopiclone)
B Strattera (atomoxetine)
C Emend (aprepitant)
D Geodon (ziprasidone)
E Comtan (entacapone)
F Cymbalta (duloxetine)
G Amerge (naratriptan)
H Lyrica (pregabalin)
I Aricept (donepezil)
J Rilutek (riluzole)

Back 4

B Strattera (atomoxetine)

Front 5

This medication is indicated to treat neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, symptoms of fibromyalgia, and as an adjunct to treatment of partial-onset seizures. It is available as 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The initial dosage for all of the indications is 50 mg 3 times daily or 75 mg twice daily. The dosage is then increased to meet the needs of the patient. The usual maintenance dosage to treat neuropathic pain associated with diabetic neuropathy is 100 mg 3 times daily; to treat post herpetic neuralgia, 75-150 mg twice daily, and up to 300 mg twice daily in patients who are still experiencing herpetic neuralgia pain after 4 weeks of treatment. The usual maintenance dosage to treat fibromyalgia is 300-450 mg/day. When used as adjunctive treatment of partial-onset seizure, the maintenance dosage is usually 150 mg twice daily, which may be increased to 300 mg twice daily. The dosage should be reduced in patients with impaired kidney function. The most common adverse reactions to this medication are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and difficulty with concentration/attention.



A Lunesta (eszopiclone)
B Strattera (atomoxetine)
C Emend (aprepitant)
D Geodon (ziprasidone)
E Comtan (entacapone)
F Cymbalta (duloxetine)
G Amerge (naratriptan)
H Lyrica (pregabalin)
I Aricept (donepezil)
J Rilutek (riluzole)

Back 5

H Lyrica (pregabalin)

Front 6

Indicated to treat schizophrenia and episodes of acute mania in bipolar disease, this medication is available as 20 mg, 40 mg, 60 mg, and 80 mg capsules, and as a 20 mg/mL solution for injection (after the lyophilized powder is reconstituted). The initial dosage to treat schizophrenia is 20 mg twice daily, titrated to a maximum maintenance dosage of 80 mg twice daily. Dosages greater than 80 mg twice daily are not recommended because of safety concerns. Dosage increases should be made in intervals of 2 days or more. The usual dosage to treat bipolar mania is 40 mg twice daily with food on the first day, increased to 60-80 mg on the second day. The maintenance dosage is 40-80 mg based on the patient's response to the drug. The injectable form of this medication is used to treat acute agitation in patients with schizophrenia, with a dosage of 10 mg every 2 hours or 20 mg every 4 hours administered intramuscularly (IM) to a maximum dosage of 40 mg per day. The most common adverse effect in patients treated for schizophrenia is somnolence. Common adverse effects in patients treated for bipolar mania include somnolence, dizziness, akathisia, and extrapyramidal symptoms such as extrapyramidal syndrome, hypertonia, dystonia, dyskinesia, hypokinesia, tremor, paralysis, and twitching. This medication has a black box warning that states this drug is associated with an increased mortality in elderly patients with dementia-related psychosis.



A Lunesta (eszopiclone)
B Strattera (atomoxetine)
C Emend (aprepitant)
D Geodon (ziprasidone)
E Comtan (entacapone)
F Cymbalta (duloxetine)
G Amerge (naratriptan)
H Lyrica (pregabalin)
I Aricept (donepezil)
J Rilutek (riluzole)

Back 6

D Geodon (ziprasidone)

Front 7

This medication is indicated to treat amyotrophic lateral sclerosis (ALS), a condition that is thought to result from the injury of motor neurons by glutamate. Although the mechanism of action of this medication is unknown, one mechanism is believed to be the inhibition of the release of glutamate. The medication is available as 50 mg tablets. The usual dosage is 50 mg every 12 hours. Common side effects are nausea, dizziness, decreased lung function, and asthenia (weakness).



A Lunesta (eszopiclone)
B Strattera (atomoxetine)
C Emend (aprepitant)
D Geodon (ziprasidone)
E Comtan (entacapone)
F Cymbalta (duloxetine)
G Amerge (naratriptan)
H Lyrica (pregabalin)
I Aricept (donepezil)
J Rilutek (riluzole)

Back 7

J Rilutek (riluzole)